Literature DB >> 22644715

Toward tailored medicine (and beyond): the phaeochromocytoma and paraganglioma model.

Vincenzo Cuccurullo, Luigi Mansi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22644715     DOI: 10.1007/s00259-012-2156-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  16 in total

1.  False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.

Authors:  Jay S Fonte; Jeremyjones F Robles; Clara C Chen; James Reynolds; Millie Whatley; Alexander Ling; Leilani B Mercado-Asis; Karen T Adams; Victoria Martucci; Tito Fojo; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2012-02-13       Impact factor: 5.678

Review 2.  Imaging of NETs with PET radiopharmaceuticals.

Authors:  V Ambrosini; P Tomassetti; R Franchi; S Fanti
Journal:  Q J Nucl Med Mol Imaging       Date:  2010-02       Impact factor: 2.346

3.  Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.

Authors:  Lucia Martiniova; Shiromi M Perera; Frederieke M Brouwers; Salvatore Alesci; Mones Abu-Asab; Amanda F Marvelle; Dale O Kiesewetter; David Thomasson; John C Morris; Richard Kvetnansky; Arthur S Tischler; James C Reynolds; Antonio Tito Fojo; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2011-01-13       Impact factor: 5.678

4.  Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.

Authors:  Kathryn S King; Clara C Chen; Dimitrios K Alexopoulos; Millie A Whatley; James C Reynolds; Nicholas Patronas; Alexander Ling; Karen T Adams; Paraskevi Xekouki; Howard Lando; Constantine A Stratakis; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2011-07-13       Impact factor: 5.958

5.  Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma.

Authors:  Makoto Fukuoka; Junichi Taki; Takafumi Mochizuki; Seigo Kinuya
Journal:  Clin Nucl Med       Date:  2011-01       Impact factor: 7.794

6.  A comparison of the performance of ⁶⁸Ga-DOTATATE PET/CT and ¹²³I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma.

Authors:  J B Maurice; R Troke; Z Win; R Ramachandran; A Al-Nahhas; M Naji; W Dhillo; K Meeran; A P Goldstone; N M Martin; J F Todd; F Palazzo; T Tan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-20       Impact factor: 9.236

7.  Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.

Authors:  Vittoria Rufini; Giorgio Treglia; Paola Castaldi; Germano Perotti; Maria Lucia Calcagni; Salvatore Maria Corsello; Guido Galli; Stefano Fanti; Alessandro Giordano
Journal:  Nucl Med Commun       Date:  2011-07       Impact factor: 1.690

Review 8.  Meta-iodobenzylguanidine and analogues: chemistry and biology.

Authors:  G Vaidyanathan
Journal:  Q J Nucl Med Mol Imaging       Date:  2008-12       Impact factor: 2.346

Review 9.  Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging.

Authors:  B Havekes; E W Lai; E P M Corssmit; J A Romijn; H J L M Timmers; K Pacak
Journal:  Q J Nucl Med Mol Imaging       Date:  2008-12       Impact factor: 2.346

10.  18F-FDOPA: a multiple-target molecule.

Authors:  Heikki Minn; Saila Kauhanen; Marko Seppänen; Pirjo Nuutila
Journal:  J Nucl Med       Date:  2009-11-12       Impact factor: 10.057

View more
  3 in total

1.  Could 68Ga-somatostatin analogues replace other PET tracers in evaluating extra-adrenal paragangliomas?

Authors:  Giorgio Treglia; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12       Impact factor: 9.236

2.  Is there a clinical usefulness for radiolabeled somatostatin analogues beyond the consolidated role in NETs?

Authors:  Vincenzo Cuccurullo; Giuseppe Danilo Di Stasio; Maria Rosaria Prisco; Luigi Mansi
Journal:  Indian J Radiol Imaging       Date:  2017 Oct-Dec

3.  99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases).

Authors:  Vittorio Briganti; Vincenzo Cuccurullo; Valentina Berti; Giuseppe D Di Stasio; Flavia Linguanti; Francesco Mungai; Luigi Mansi
Journal:  Curr Radiopharm       Date:  2020
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.